This SynCon DNA vaccine targeting FSHR broke immune tolerance, elicited potent long-lasting CD8+ and CD4+ responses, and delayed FSHR+ tumor progression by enhancing antitumor immunity, specifically CD8+ cytotoxic T lymphocyte (CTL) responses (15). Here, CD8A is linked to neoplasm.